Boston Scientific (BSX) Q1 2026 (USD): Adj. EPS 0.80 (exp. 0.79), Revenue 5.2bln (exp. 5.17bln); Next Qtr. Adj. EPS 0.82-0.84 (exp. 0.86); Current FY EPS 3.34-3.41 (prev. guided 3.43-3.49, exp. 3.46)

Boston Scientific's Q1 results slightly beat expectations on both adjusted EPS and revenue, suggesting solid performance thus far.

Newsquawk StaffPublished On the live feed at 3 more headlines followed before this page went public
Newsquawk headlinesUTC

Russia reportedly mulls a windfall levy on some businesses amid war spending, Bloomberg reports

ECB's Elderson: Speech on climate policy, conducted 15 April 2026

Boston Scientific (BSX) Q1 2026 (USD): Adj. EPS 0.80 (exp. 0.79), Revenue 5.2bln (exp. 5.17bln); Next Qtr. Adj. EPS 0.82-0.84 (exp. 0.86); Current FY EPS 3.34-3.41 (prev. guided 3.43-3.49, exp. 3.46)

AT&T (T) Q1 2026 (USD): adj. EPS 0.57 (exp. 0.55), Revenue 34.5bln (exp. 31.25bln)

GE Vernova Inc. (GEV) Q1 2026 (USD): EPS -- (exp. 1.97), Revenue 9.3bln (exp. 9.18bln); raises guidance, now sees FY revenue 44.5-45.5bln (prev. guided 44-45bln, exp. 44.65bln)

Open the platform and use it. The whole workspace is free to try, with no signup and no card. When you want the headlines arriving live instead of on a delay, Newsquawk Pro is £24.99 for 7 days.

Free. No signup, no card.
Context

However, the guidance for next quarter and the current fiscal year has been lowered, which could raise concerns about future growth. This mixed outcome may impact market sentiment around BSX and the healthcare equipment sector more broadly, prompting a cautious stance among investors.

Related headlines

The whole workspace, free to try.

Try it free